¼±Åà - È­»ìǥŰ/¿£ÅÍŰ ´Ý±â - ESC

 
"contact activation cofactor"¿¡ ´ëÇÑ °Ë»ö °á°úÀÔ´Ï´Ù. °Ë»ö °á°ú º¸´Â µµÁß¿¡ Tab ۸¦ ´©¸£½Ã¸é °Ë»ö âÀÌ ¼±Åõ˴ϴÙ.
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ À¯»ç °Ë»ö °á°ú : 1 ÆäÀÌÁö: 1
¿µ¹® activation ÇÑ±Û È°¼º, Ȱ¼ºÈ­
¼³¸í   
  ÀϹÝÀûÀ¸·Î, »ýü³ª »ýü ¹°ÁúÀÌ ±× ±â´ÉÀ» È°¹ßÇϰԠ³ªÅ¸³»°Ô µÇ´Â °Í, ¿¹¸¦ µé¸é ¨ç Ã˸Šµî¿¡¼­, ±× Ç¥¸é »óÅÂÀÇ º¯È­³ª, ´Ù¸¥ ¹°ÁúÀǠ÷°¡ µî¿¡ ÀÇÇÏ¿©, ±× ±â´ÉÀÌ ÇöÀúÇϰԠ³ô¾ÆÁö´Â °Í. ¨è È¿¼ÒÀü±¸Ã¼ÀǠȰ¼ºÈ­·Î¼­ È¿¼ÒÀÛ¿ëÀ» °¡ÁöÁö ¾Ê´Â È¿¼Ò Àü±¸Ã¼°¡ È°¼ºÀִ ȿ¼Ò·Î º¯È­´Â °Í. ¶Ç È²È­¼ö¼Ò³ª ½Ã¾ÈÈ­¼ö¼Ò»ê µîÀ¸·Î ÆÄÆÄÀÎÀ̠Ȱ¼ºÈ­µÇ´Â °æ¿ìµµ ÀÖ´Ù.
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • cofactor
    º¸Á¶ÀÎÀÚ
  • ristocetin cofactor
    ¸®½ºÅ似ƾº¸Á¶ÀÎÀÚ
  • activation
    Ȱ¼ºÈ­
  • activation analysis
    Ȱ¼ºÈ­ºÐ¼®, ¹æ»çÈ­ºÐ¼®
  • activation energy
    Ȱ¼ºÈ­¿¡³ÊÁö
  • activation factor
    Ȱ¼ºÀÎÀÚ
  • activation gate
    °³¹æ°ü¹®
  • activation process
    Ȱ¼ºÈ­°úÁ¤
  • complement activation
    º¸Ã¼È°¼ºÈ­, µµ¿òüȰ¼ºÈ­
  • photochemical activation
    ±¤È­ÇÐȰ¼ºÈ­
  • sleep activation
    ¼ö¸éȰ¼ºÈ­
  • ventricular activation
    ½É½ÇȰ¼ºÈ­
  • ventricular activation time
    ½É½ÇÈïºÐ½Ã°£
  • affective contact
    Á¤µ¿Á¢ÃË
  • allergic contact dermatitis
    ¾Ë·¹¸£±âÁ¢ÃËÇǺο°
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 9 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • cofactor
    º¸Á¶ÀÎÀÚ
  • activation
    Ȱ¼º, Ȱ¼ºÈ­, ´Éµ¿È­
  • activation factor
    Ȱ¼ºÀÎÀÚ
  • contact
    Á¢ÃË, Á¢ÃË-
  • proximal contact
    ÀÎÁ¢
  • allergic contact dermatitis
    ¾Ë·¹¸£±âÁ¢ÃËÇǺο°
  • photoallergic contact dermatitis
    ±¤¾Ë·¹¸£±âÁ¢ÃËÇǺο°
  • contact urticaria syndrome
    Á¢Ã˵ε巯±âÁõÈıº
  • contact urticaria
    Á¢Ã˵ε巯±â
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • cofactor
    º¸Á¶ÀÎÀÚ
  • ristocetin cofactor
    ¸®½ºÅ似ƾº¸Á¶ÀÎÀÚ
  • activation
    Ȱ¼º, Ȱ¼ºÈ­
  • activation detector
    Ȱ¼ºÈ­Å½Áö±â
  • activation energy
    Ȱ¼º¿¡³ÊÁö
  • activation factor
    Ȱ¼ºÀÎÀÚ
  • activation gate
    °³¹æ°ü¹®
  • activation process
    Ȱ¼ºÈ­°úÁ¤
  • activation analysis
    Ȱ¼ºÈ­ºÐ¼®, ¹æ»çÈ­ºÐ¼®
  • complement activation
    µµ¿òüȰ¼º, º¸Ã¼È°¼º
  • photochemical activation
    ±¤È­ÇÐȰ¼ºÈ­
  • sleep activation
    ¼ö¸éȰ¼º
  • ventricular activation
    ½É½ÇÈïºÐ
  • ventricular activation time
    ½É½ÇÈïºÐ½Ã°£
  • affective contact
    Á¤µ¿Á¢ÃË
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • heparin cofactor II
    ÇìÆÄ¸°º¸Á¶ÀÎÀÚ II
  • Contact lens
    ÄÜÅÃÆ®·»Áî
  • affective contact
    Á¤µ¿Àû Á¢ÃË(¡­ïÈõº).
  • allergic contact dermatitis
    ¾Ë·¹¸£±â Á¢ÃËÇǺο°( ïÈõºù«Ý±æú)
  • allergy, contact
    Á¢Ã˼º ¾Ë·¹¸£±â
  • arc of contact
    Á¢Ã˸é, Á¢ÃËÆø
  • hard contact lens
    ÇϵåÄÜÅÃÆ®·»Áî, °æ¼ºÄÜÅÃÆ®·»Áî
  • hydrogel contact lens
    ÇÔ¼öÄÜÅÃÆ®·»Áî
  • hydrophilic contact lens
    Ä£¼öÄÜÅÃÆ®·»Áî
  • hypersensitivity, contact
    Á¢Ã˼º °ú¹Î¹ÝÀÀ
  • immediate contact
    Á÷Á¢Àü¿°(Ì¤ËøËøËç).
  • indirect contact
    °£Á¢Á¢ÃË.
  • indirect contact infection
    °£Á¢Á¢Ã˰¨¿° <Àü¿°>.
  • inhibition, contact
    Á¢Ã˼º Áõ½Ä¾ïÁ¦
  • proximal contact
    ÀÎÁ¢(ìäïÈ).
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • cofactor
    º¸Á¶ÀÎÀÚ.
  • cofactor
    Á¶ÀÎÀÚ
  • heparin cofactor II
    ÇìÆÄ¸°º¸Á¶ÀÎÀÚ II
  • ristocetin cofactor
    ¸®½ºÅ似ƾº¸Á¶ÀÎÀÚ(¡­ÜÍð¾ì×í­)
  • activation
    Ȱ¼ºÈ­
  • activation
    Ȱ¼ºÈ­(üÀàõûù).
  • activation analysis
    ¹æ»çÈ­ºÐ¼®, Ȱ¼ºÈ­ºÐ¼®
  • activation analysis
    Ȱ¼ºÈ­ºÐ¼®(¡­ÝÂà°), ¹æ»çÈ­(Û¯ÞÒûù)ºÐ¼®.
  • activation detector
    Ȱ¼ºÈ­ ŽÁö±â
  • activation energy
    Ȱ¼ºÈ­¿¡³ÊÁö
  • activation gate
    °³¹æ °ü¹®(ËÒÛÁμڦ)
  • activation process
    Ȱ¼ºÈ­°úÁ¤.
  • activation, polyclonal
    ´Ù¼¼Æ÷±ºÈ°¼º, ¿©·¯¹«¸®È°¼º
  • activation, polyclonal B cell
    ´Ù¼¼Æ÷±º B¼¼Æ÷Ȱ¼º, ¿©·¯¹«¸® B¼¼Æ÷Ȱ¼º
  • c3, activation
    C3, Ȱ¼º (¡­üÀàõ)
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 1 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • Contact area
    ´ê´ÂºÎºÐ
    [¿¾ ¿ë¾î] Á¢Ã˸é
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 1 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • contact activation cofactor
    "Á¢ÃËȰ¼º º¸ÀÎÀÚ(ïÈõºüÀàõÜÍì×í­), (ÔÒ) high molecular weight kininogen"
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • cofactor
    º¸(Á¶)ÀÎÀÚ(ÜÍ(ð¾)ì×í­)
  • cofactor-requiring mutant
    º¸(Á¶)ÀÎÀڿ䱸 º¯ÀÌü(ÜÍ(ð¾)ì×í­é©Ï´Ü¨ì¶ô÷)
  • platelet cofactor I
    Ç÷¼ÒÆÇ(úìá³÷ù) º¸ÀÎÀÚ (ÜÍì×í­) I
  • platelet cofactor II
    Ç÷¼ÒÆÇ(úìá³÷ù) º¸ÀÎÀÚ(ÜÍì×í­) II
  • contact factor
    "Á¢ÃËÀÎÀÚ(ïÈõºì×í­), (ÔÒ) Hageman factor"
  • contact guidance
    Á¢Ã˾ȳ»(ïÈõºäÐÒ®)
  • contact hypersensitivity
    Á¢Ã˰ú¹ÎÁõ(ïÈõºÎ¦ÚÂñø)
  • contact inhibition
    Á¢ÃËÀúÇØ(ïÈõºîÁúª)
  • contact map
    Á¢ÃËÁöµµ(ïÈõºò¢Óñ)
  • contact surface
    Á¢Ã˸é(ïÈõºØü)
  • activation
    Ȱ¼ºÈ­ (üÀàõûù)
  • activation analysis
    Ȱ¼ºÈ­ºÐ¼® (üÀàõûùÝÂà°)
  • activation energy
    Ȱ¼ºÈ­(üÀàõûù)¿¡³ÊÁö
  • activation stage
    Ȱ¼ºÈ­±â(üÀàõûùÑ¢)
  • amino acid activation
    ¾Æ¹Ì³ë»ê(ß«) Ȱ¼ºÈ­(üÀàõûù)
KI ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 6 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • contact
    Á¢ÃË
  • contact compound scan
    Á¢Ã˺¹ÇÕ½ºÄµ
  • contact dermatitis
    Á¢ÃËÇǺο°
  • contact irradiation
    ±ÙÁ¢Á¶»ç¹ý
  • contact radiography
    ±ÙÁ¢ÃÔ¿µ¼ú
  • contact scan
    Á¢Ã˽ºÄµ
KMLE ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 1
CoF cobra factor; cofactor
F()R:C factor ( ) related cofactor activity
HC hair cell; hairy cell; handicapped; head circumference; head compression; health care; healthy contr...
HCF [fetal] head-to-cervix force; heparin cofactor; hereditary capillary fragility; highest common facto...
MCP maximum closure pressure; maximum contraction pattern; malanocortin receptor; melphalan, cyclophosph...
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 1
HCII Heparin Cofactor II
MCP Membrane Cofactor Protein
MoCo Molybdenum cofactor
RiCof Ristocetin Cofactor
R:Cof Ristocetin cofactor
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
  • ristocetin cofactor
    ¸®½ºÅ似ƾ º¸Á¶ ÀÎÀÚ
  • activation
    Ȱ¼ºÈ­
    Ȱ¼ºÈ­ÇÏ´Â ÀÛ¿ëÀ̳ª °úÁ¤.
  • activation of muscle
    ±ÙÀ°ÀÇ È°¼ºÈ­
    ±ÙÀ° Á¶Á÷À¸·Î ¿¡³ÊÁö°¡ ¹æÃâµÇ¾î ±ÙÀ°ÀÇ ¼öÃàÀ» ÀÏÀ¸Å°´Â °Í.
  • activation process
    Ȱ¼ºÈ­ °úÁ¤
  • co-activation
    »óÈ£ Ȱ¼º
  • complement activation
    º¸Ã¼ Ȱ¼º ÀÛ¿ë, º¸Ã¼ Ȱ¼ºÈ­
  • heat of activation
    Ȱ¼ºÈ­ ¿­
  • polyclonal activation
    ´Ù¼ö Ŭ·Ð Ȱ¼º
  • receptor activation
    ¼ö¿ëü Ȱ¼ºÈ­, ¼ö¿ë±â Ȱ¼ºÈ­
  • secondary activation
    ÀÌÂ÷Àû Ȱ¼º
  • sympathetic activation
    ±³°¨½Å°æ°è Ȱ¼º
  • allergic contact reaction
    ¾Ë·¯Áö¼º Á¢ÃË ¹ÝÀÀ
  • allergic-toxic contact stomatitis
    ¾Ë·¯Áö-µ¶¼º Á¢ÃË ±¸³»¿°
  • assisted mediotrusive contact
    ³»Ãø¹æ À¯µµ Á¢ÃË
  • balancing occlusal contact
    ±ÕÇü ±³ÇÕ Á¢ÃË
    ºÎÀûÀýÇÑ ¿ë¾î. nonworking occlusal contactÀ» º¸½Ã¿À.
CancerWEB ¿µ¿µ ÀÇÇлçÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
cobra venom cofactor <enzyme> A glycine-rich, heat-labile beta-glycoprotein found in blood. It is a proactivator of complement 3 in the alternate pathway of complement activation. Factor b is converted by factor d to c3 convertase.
Registry number: EC 3.4.21.47
(12 Dec 1998)
molybdenum cofactor A complex of molybdenum and molybdopterin required for a number of enzymes. A deficiency of this cofactor will result in lower activities of sulfite oxidase, xanthine dehydrogenase, and aldehyde oxidase causing elevated levels of sulfite, thiosulfite, xanthine, etc.
(05 Mar 2000)
cofactor <biochemistry> Inorganic complement of an enzyme reaction, usually a metal ions.
See: coenzyme.
(18 Nov 1997)
platelet cofactor I A coagulation (clotting) factor. Classic haemophilia (haemophilia A) is due to a congenital deficiency in the amount (or activity) of factor VIII. Factor VIII is also known as antihemophiliac factor (AHF) or antihemophiliac globulin (AHG). The gene for factor VIII (that for classic haemophilia) is on the X chromosome so females can be silent carriers without symptoms and males can be haemophiliacs.
(12 Dec 1998)
platelet cofactor II <chemical> Storage-stable blood coagulation factor acting in the intrinsic pathway. Its activated form, ixa, forms a complex with factor viii and calcium on platelet factor 3 to activate factor x to xa. Deficiency of factor ix results in christmas disease (haemophilia b).
Chemical name: Blood-coagulation factor IX
(12 Dec 1998)
heparin cofactor II <chemical> A sulfated plasma protein with the mw of approximately 66kda. The protein is an inhibitor of thrombin in plasma that is activated by dermatan sulfate or heparin. It is a member of the serpin superfamily.
Pharmacological action: serine proteinase inhibitors.
Chemical name: Heparin cofactor II
(12 Dec 1998)
activation <radiobiology> Activation occurs when a particle interacts with an atomic nucleus, shifting the nucleus into an unstable state, and causing it to become radioactive.
In fusion research, where deuterium-tritium is a common fuel mixture, the neutron released when (D + T) combine to form (4He + n) can activate the reactor structure. In this case the 4He is inert, the neutron sticks to another nucleus, and the neutron + nucleus reaction creates an actvation product. Sometimes called radioactivation.
See: activation product, activation analysis.
(09 Oct 1997)
activation analysis <radiobiology> Method for identifying and measuring chemical elements in a sample of material. Sample is first made radioactive by bombardment with neutrons, charged particles, or gamma rays.
Newly formed radioactive atoms in the sample then give off characteristic radiations (such as gamma rays) that tell what kinds of atoms are present, and how many.
(09 Oct 1997)
activation energy <chemistry> The amount of energy (expressed in joules) that is needed to convert all the molecules in one mole of a reacting substance from a ground state to the transition state.
(06 May 1997)
activation product <radiobiology> The unstable nucleus formed when activation occurs. (See activation above.)
(09 Oct 1997)
amino acid activation The first step of protein synthesis, whereby an amino acid reacts with adenosine triphosphate in the presence of aminoacyl RNA synthetase to produce an amino acid adenylate, which provides the energy necessary for the attachment of the amino acid to a specific transfer RNA molecule.
(12 Dec 1998)
macrophage activation The process of altering the morphology and functional activity of macrophages so that they become avidly phagocytic. It is initiated by lymphokines, such as the macrophage activation factor (maf) and the macrophage migration-inhibitory factor (mmif), immune complexes, c3b, and various peptides, polysaccharides, and immunologic adjuvants.
(12 Dec 1998)
gene activation The process of activation of a gene so that it is expressed at a particular time. This process is crucial in growth and development.
(05 Mar 2000)
Gibbs energy of activation The Gibbs energy that must be added to that already possessed by a molecule or molecules in order to initiate a reaction.
(05 Mar 2000)
virus activation The mechanism by which latent viruses, such as genetically transmitted tumour viruses or prophages of lysogenic bacteria, are induced to replicate and are released as infectious viruses. It may be effected by various endogenous and exogenous stimuli, including B-cell lipopolysaccharides, glucocorticoid hormones, halogenated pyrimidines, ionizing radiation, ultraviolet light, and superinfecting viruses.
(12 Dec 1998)
ÇÑ¿µ/¿µÇÑ »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • cofactor
    °øµ¿ ÀÎÀÚ;º¸Á¶ ¿äÀÎ;°øÅë ÀÎÀÚ;¿©Àμö(ÀÎÀÚ)
  • activation
    Ȱµ¿ÀûÀ¸·Î Çϱâ;Ȱ¼ºÈ­;ºÎ´ë ½Å¼³(Æí¼º)
  • neutron activation analysis
    Áß¼ºÀÚ(À¯µµ)¹æ»çÈ­ ºÐ¼®
  • contact
    Á¢ÃË,±³Á¦,¿¬¶ôÇÏ´Ù,Á¢ÃËÇÏ´Ù
  • contact
    Á¢ÃË;¸Â´êÀ½(touching);±³Á¦;Ä£±³(associations)¿¬¶ô(À» ÃëÇÔ);¿¬ÁÙ(connection);Á¢ÃË;È¥¼±;»óÁ¢;Á¢ÃË;º¸±Õ¿ëÀÇÀÚ;Á¢ÃË(°¨);Á¢Àü;(ºñÇà±â¿¡ ÀÇÇÑ Áö»ó ÀüÁøºÎ´ë¿ÍÀÇ)¿¬¶ô;À°¾È¿¡ ÀÇÇÑ Áö»ó°üÂû;±³½Å;(»ó¾÷Àû¸ñÀûÀ¸·Î)±³¼·Çϰí ÀÖ´Â »ç¶÷;Á߰迪ÇÒÀ» ÇÒ¼öÀÖ´Â »ç¶÷;=CONTACT L
  • contact action
    Á¢ÃËÀÛ¿ë
  • contact agent
    Ã˸Å;Á¢ÃËÁ¦(catalyzer)
  • contact approach
    À¯½Ã°è ÁøÀÔ
  • contact breaker
    (Àü·ùÀÇ) Â÷´Ü±â
  • contact catalysis
    Á¢ÃË(Ã˸Å)ÀÛ¿ë
  • contact dermatitis
    Á¢ÃË ÇǺο°
  • contact electricity
    Á¢ÃËÀü±â
  • contact flying(flight)
    Á¢ÃË ºñÇà;À¯½Ã°èºñÇà
  • contact high
    °¨¿°(°£Á¢) µµÃë(¸¶¾àµµÃëÀÚ¿Í Á¢Çϰųª ¿¬±â³¿»õ·Î ÃëÇϱâ)
  • contact ingibition
    Á¢ÃËÀúÁö(¹è¾ç¼¼Æ÷°¡ ¼­·Î Á¢ÃËÇÏ¿© ±â´ÉÀÌ Á¤ÁöµÇ±â)
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
KMLE ¾àǰ/ÀǾàǰ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
KMLE ¾àǰ/ÀǾàǰ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
KMLE ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
ÀÇÇÐ³í¹® ¾àÀÚ(Pubmed/Entrez) °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
CancerWEB ¿µ¿µ ÀÇÇлçÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
MeSH(Medical Subject Headings) ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 1
MeSH(Medical Subject Headings) À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü ¸ÂÃã °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü À¯»ç °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ ¸ÂÃã °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 1
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ À¯»ç °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 1
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference ¸ÂÃã °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference À¯»ç °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition ¸ÂÃã °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition À¯»ç °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 1
KMLE À¥ ¿ë¾î ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
KMLE À¥ ¿ë¾î À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
ÇÑ¿µ/¿µÇÑ »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
WordNet ÀÏ¹Ý ¿µ¿µ »çÀü °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü ¸ÂÃã °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü À¯»ç °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 1
ÅëÇÕ°Ë»ö ¿Ï·á